NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma Inc (NASDAQ:TBPH) issued its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by $0.06. The biopharmaceutical company earned $29.50 million during the quarter, compared to analysts' expectations of $18.33 million. View Theravance Biopharma's Earnings History.

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Theravance Biopharma.

5 brokerages have issued 12 month target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $36.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

News headlines about TBPH stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Theravance Biopharma earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Theravance Biopharma.

Theravance Biopharma saw a decrease in short interest in January. As of January 15th, there was short interest totalling 2,640,000 shares, a decrease of 5.4% from the December 31st total of 2,790,000 shares. Based on an average daily volume of 307,900 shares, the short-interest ratio is presently 8.6 days. Approximately 6.9% of the company's shares are sold short. View Theravance Biopharma's Current Options Chain.

Some companies that are related to Theravance Biopharma include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO) and PPD (SDGR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Exelixis (EXEL), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Immunomedics (IMMU), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX) and Verastem (VSTM).

Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Link Fund Solutions Ltd (9.25%), State Street Corp (1.69%), Chescapmanager LLC (1.67%), Geode Capital Management LLC (1.08%), Jacobs Levy Equity Management Inc. (0.80%) and Candriam Luxembourg S.C.A. (0.49%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

TBPH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Citigroup Inc., Virtus ETF Advisers LLC, Bank of America Corp DE, Chicago Equity Partners LLC, New York State Common Retirement Fund, Nisa Investment Advisors LLC and ProShare Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

TBPH stock was purchased by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Chescapmanager LLC, Newtyn Management LLC, Laurion Capital Management LP, Jacobs Levy Equity Management Inc., Credit Suisse AG, First Trust Advisors LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Theravance Biopharma.

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TBPH stock can currently be purchased for approximately $23.77.

Theravance Biopharma has a market capitalization of $1.35 billion and generates $73.41 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.

The official website for Theravance Biopharma is http://www.theravance.com/.

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]